Table 2.

Summary of details from cases with abnormal LFTs after anti-TNF use

Age (years)	Disease	Ethnicity	Anti-TNF	Anti-TNF dosing	Duration of therapy at time of LFT rise	Peak ALT (U/l)	Peak AST (U/l)	Peak bilirubin (mg/dl)	Peak Alk phos (U/l)	Time to improvement after stopping
56	PA	White	Infliximab	3 mg/kg Q8 weeks	5 months	75	38	0.6	125	2 months
47	RA	Hispanic	Etanercept	50 mg Q week	1 month	112	65	0.8	117	4 months
50	CD	Hispanic	Infliximab	5 mg/kg Q8 weeks	8 months	112	54	0.7	81	7 months
55	RA	White	Adalimumab	40 mg Q2 weeks	3 months	104	88	1.0	121	7 months
66	PA	White	Etanercept	25 mg Q2 weeks	12 months	69	63	0.7	72	Did not stop
45	RA	Hispanic	Etanercept	50 mg Q week	4 months	180	75	0.9	116	Did not stop
33	AS	White	Infliximab	3 mg/kg Q10 weeks	1 month	71	41	1.6	76	Did not stop
49	RA	Hispanic	Adalimumab	40 mg Q2 weeks	63 months	163	76	1.5	172	8 months

Alk phos, alkaline phosphatase; ALT, alanine transaminase; AS, ankylosing spondylitis; AST, aspartate transaminase; CD, Crohn’s disease; LFT, liver function test; PA, psoriatic arthritis; RA, rheumatoid arthritis; TNF, tumor necrosis factor.